background, introduction, statutory authority, introduction to risk-based approach larisa rudenko,...
TRANSCRIPT
Background, Introduction, Statutory Authority, Introduction to Risk-Based Approach
Larisa Rudenko, PhD, DABT
What is Animal Biotechnology?
Assisted Reproductive Technologies Help distribute genetics beyond natural matings AI, semen sexing, in vitro fertilization,
embryo transfer, embryo splitting 1300s-present
Cloning More rapid distribution of naturally occurring desirable traits in
breeding stock 1990s-present in livestock
Genetic Engineering Introduces/modifies genes not naturally occurring to introduce
new traits 1980s-present in livestock
Animal Biotechnology (from the Regulator’s Perspective)
Genetic Engineering
GE Animals withHeritable Constructs
Animals with Non-Heritable
Constructs
Natural Breeding
AI ± FrozenSemen Cloning
EmbryoSplit
in vitroFertilization
Selective Breeding
Animal cloning is on a continuum with other ARTS……...
Genetic engineering is a distinctly different technology
Animal Biotechnology (from the Regulator’s Perspective)
The previous slide presents a series of boxes on a horizontal axis that indicate a continuum of assisted reproductive technologies currently in use in US commercial agriculture ranging from natural breeding, selective breeding, artificial insemination/frozen semen, in vitro fertilization, embryo splitting, and ending up with cloning. It is intended to show that cloning falls on that continuum. On the horizontal below is a dotted line and a box saying "genetic engineering,” which indicates that genetic engineering does not fall on that same continuum. Finally, the slide indicates a bifurcation of the term "genetic engineering" to indicate that GE animals can contain both heritable and non-heritable constructs.
Challenges for the Technology
Funding (basic research and commercialization) Effective communications
Unbiased, credible sources of information Not overpromising the technology
A tool in the toolbox No panaceas
Faith in the regulatory system Public acceptance
Challenges for the Agency
Getting the word out Educating investigators Staying in touch with stakeholders
Follow-on guidances Coordination across USG Continuing international outreach Continuing to have faith
in the regulatory system maintained
Possible Solutions
Do the work Work harder at constructive engagements Abandon stale arguments
Hazards vs risks“Scientists” vs “the public”
Consider new approaches to sustainability Avoid reductionist approaches
Transparency
“Agency interested in increasing transparency” (Guidance 187)
What does that mean? Transparency of processes
Data acquisition? Interpretation?
Transparency of deliberations Conclusions? What do they mean?
Public VMAC meeting prior to approvals
Definitions, Relationships, Standards
Harm ≡ an adverse outcomeHazard ≡ substance or activity that has the potential to cause a harmRisk ≡ conditional probability of an adverse outcome provided that
exposure to a receptor has occurred…or
Risk foutcome (exposure, hazard), or
“the likelihood of harm”
Receptor ≡ individual or population experiencing risk
Safety ….reasonable certainty of no harm (established standard)
Intended, Unintended, Direct, Indirect Effects/Risks
Terms used to sort outcomesDirect/Indirect categorize based on
mechanism of actionIntended/Unintended categorize based on
objective of modification
Hazard to What, Risk to Whom?
rDNA construct produces potential hazard(s) in rDNA animals. These may pose health risks to the animals.
Humans/animals consuming edible products from GE animals may/may not experience food consumption risks.
GE Animal Guidance
Final 1/15/2009
Guidance for Industry #187 - Regulation of Genetically Engineered Animals Containing Heritable Recombinant DNA Constructs
http://www.fda.gov/AnimalVeterinary/DevelopmentApprovalProcess/GeneticEngineering/GeneticallyEngineeredAnimals/default.htm
Goal/Structure of Draft Guidance
Three parts
Clarification of FDA’s continued regulation of GE animals under NADA provisions of FFDCA
Congruence with existing regulations (21 CFR 511 (INAD) and 21 CFR 514 (NADA)
Recommendations on how sponsors can prepare data and information for FDA to review
Scope
All GE animals covered; specific recommendations for those with heritable rDNA constructs
Explicitly includes biopharm animals Enforcement discretion possible for low risk
applications INAD/NADA processes Post-approval responsibilities
Key Concepts -1Statutory/Scope
Definition of “article” rDNA construct intended to affect the structure or
function of the animal
“All GE animals derived from the same tx event contain the same article, and subject to evaluation under a single new animal drug application.” (Guidance 187 p 6)
No products in commerce without FDA approval (minor exceptions enforcement discretion)
Key Concepts -2Risk-Based Approach
Each GE Animal/rDNA construct event poses unique risk(s)Specific set of risk questionsSpecific set of data/information driven responses
Case-by-case evaluation for each transformation event (i.e., each “article”)